Life sciences company IsoPlexis Corporation (IsoPlexis) said on Monday that it plans to distribute its single-cell proteomic analysis platform products in China's pharmaceutical and life sciences markets through an exclusive agreement with the leading instrumentation distributor, Tekon Biotech.
Tekon Biotech's first conference featuring IsoPlexis's systems will be held at Purple Mountain Hotel in Pudong in Shanghai, China, on 20 September 2018.
IsoPlexis' IsoCode & IsoLight systems will be available to customers through Tekon Biotech in Mainland China, Hong Kong, Taiwan and Macau.
According to IsoPlexis, its IsoCode & IsoLight system have received numerous awards as well as recognized as both The Scientist's and Fierce Life Science's #1 innovation of 2017 for the ability to provide both single-cell sensitivity and highly multiplexed and quantitative functional ELISA detection together for the first time. The IsoLight received the global Red Dot Design Award in 2018 for its ease of use.
Additionally, IsoPlexis has published data with a variety of leading US CAR-T and Cell Therapy biopharmas and academic institutions, including in the journal 'Blood', where IsoPlexis' IsoCode technology predicted whether non-Hodgkin lymphoma patients would respond to CAR-T therapy, directly from the pre-infusion Cell Product. The IsoLight is a next-generation analytics platform that profiles responses at the single cell level enabling researchers to generate a precise functional patient signature to help predict and understand complex patient response to cancer immunotherapies.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886